New England Journal of Medicine Publishes Novavax' NanoFlu Clinical Trial Data
- NanoFluTM Phase 1/2 trial data published in a peer-reviewed letter to the editor in The New England Journal of Medicine
- NanoFlu demonstrates significantly improved immune responses against a panel of homologous and drifted A(H3N2) influenza viruses compared to leading licensed egg-based, high-dose flu vaccine in older adults
- Phase 2 trial of quadrivalent NanoFlu expected to begin in third quarter of 2018
GAITHERSBURG, Md., June 13, 2018 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) today announced that The New England Journal of Medicine (NEJM) published a peer-reviewed letter to the editor detailing the positive results from Novavax' Phase 1/2 clinical trial in older adults comparing its Matrix- M(TM) adjuvanted nanoparticle seasonal influenza vaccine candidate (NanoFlu) to the leading licensed egg-based, high-dose influenza vaccine (IIV3-HD). The letter is available online at www.nejm.org/doi/full/10.1056/NEJMc1803554.
"We are pleased to be able to share the detailed data from the NanoFlu Phase 1/2 clinical trial with the broader scientific community," said Stanley C. Erck, President and Chief Executive Officer of Novavax, Inc. "The low effectiveness of seasonal influenza vaccines, and in particular the A(H3N2) component of the vaccine, during the 2017-2018 season emphasizes the need for a more effective vaccine. Our non-egg-based, recombinant nanoparticle vaccine, when coupled with Matrix-M, potentially offers broader protection against rapidly evolving drift strain variants. We believe this addresses important public health challenges caused by influenza and offers a significant advantage over current influenza vaccines."
In February 2018, Novavax reported the positive top-line results from the NanoFlu Phase 1/2 clinical trial in older adults. Details of the data, as published in this letter, include that NanoFlu in comparison to IIV3-HD induced:
- Hemagglutination inhibition (HAI) immune responses that were 28 to 64% greater against the homologous and four generations of drifted wild-type A(H3N2) influenza strains; and
- Higher HAI responses against the homologous A(H1N1) strain and comparable responses against the homologous B/Brisbane strain.
"These results showcase the potential benefit NanoFlu could have for older adults, a population challenged by poor immune responses. This population faces an urgent unmet medical need for a more effective flu vaccine, as highlighted by the severe flu season of 2017-2018," said Dr. Vivek Shinde, Executive Director, Clinical Development at Novavax and lead author of the letter. "We look forward to advancing this vaccine into the planned Phase 2 clinical trial of quadrivalent NanoFlu in the third quarter of 2018."
About the Phase 1/2 Clinical Trial
Novavax, Inc. conducted a randomized, observer-blind, comparator-controlled trial of NanoFlu (in two trivalent formulations: 45µg or 180µg total HA) against IIV3-HD in 330 healthy adults aged 60 years or older. Immunogenicity was measured by HAI and neutralization antibody responses against a panel of vaccine-homologous, and historically and forward-drifted, influenza virus strains.
About NanoFlu(TM) and Matrix M(TM)
NanoFlu is a recombinant hemagglutinin (HA) protein nanoparticle influenza vaccine candidate produced by Novavax in its SF9 insect cell baculovirus system. NanoFlu uses HA amino acid protein sequences that are substantially the same as wild-type circulating virus HA sequences. NanoFlu contains Novavax' patented saponin-based Matrix-M adjuvant, which has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes.
Novavax, Inc. is a clinical-stage biotechnology company committed to delivering novel products to prevent infectious diseases. Its RSV and NanoFlu vaccine candidates are Novavax' most advanced clinical programs and are at the forefront of its efforts to improve global health. For more information, please visit www.novavax.com.
Statements herein relating to the future of Novavax and the ongoing development of its vaccine and adjuvant products are forward-looking statements. Novavax cautions that these forward looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2017 as filed with the Securities and Exchange Commission (SEC). We caution investors not to place considerable reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and we undertake no obligation to update or revise any of the statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
Senior Manager, Investor & Public Relations
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novavax, Inc. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Inspirata Unveils Comprehensive Insight Solutions for the Cancer Care Continuum18.6.2019 13:00:00 CEST | Pressemelding
Leading digital pathology company now offers technology-enabled insight solutions Tampa, Florida, June 18, 2019 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology solution provider Inspirata today unveiled its new end-to-end capabilities for the cancer care continuum. Founded as a digital pathology company that pioneered the use of digital imaging for accurate cancer diagnoses, Inspirata now offers cancer registry abstraction and insight solutions to drive better cancer diagnosis, treatment, performance, and research. Inspirata’s comprehensive solutions reveal a clear picture of patients, allowing clinicians to make every moment matter in delivering cancer care. With an existing global footprint that serves over 100 institutions with automated cancer identification and reporting, and more than 30 hospitals and laboratories with digital pathology, Inspirata processes over 20 million patient reports per year, identifying all reports containing reportable cancer. Today, the comp
Next Green Wave Launches Bold New Line of THC Products with Grammy Nominated King Louie18.6.2019 11:29:00 CEST | Pressemelding
VANCOUVER, British Columbia, June 18, 2019 (GLOBE NEWSWIRE) -- Next Green Wave Holdings Inc. (CSE: NGW) (OTCQB: NXGWF) ("Next Green Wave", “NGW” or the "Company") is celebrating its next brand roll-out with influential Chicago hip-hop star King Louie. Through an exclusive partnership with SD Cannabis, King Louie will be launching premium flower THC products and concentrates throughout his new ‘Life of Louie’ album world-tour and appearances at selected dispensaries throughout Southern California.* Next Green Wave CEO, Leigh Hughes commented, “We’re thrilled to be collaborating on this product launch with King Louie, he is a trailblazer in the hip-hop industry and influential ambassador of cannabis culture in America. Together, we have the opportunity to shape the norms and perceptions surrounding cannabis culture and will offer consumers an elevated experience through the quality and delivery of our extracted oils and exclusive flower products.” “It’s a lifestyle for us, so it’s gonna
Bombardier to supply 30 additional FLEXITY Trams to Brussels Transportation Company18.6.2019 10:41:00 CEST | Pressemelding
Additional FLEXITY trams to boost Brussels Transport Company’s fleet capacity and meet demand for growing passenger numbers BERLIN, June 18, 2019 (GLOBE NEWSWIRE) -- Note to editors: To view the photo associated with this press release, please visit the following link: https://www.globenewswire.com/NewsRoom/AttachmentNg/94e847eb-40b7-42c3-a196-d7783859b9c9 Mobility technology leader Bombardier Transportation has received an order to supply 30 additional BOMBARDIER FLEXITY trams to the Brussels Intercommunal Transportation Company (STIB) in Belgium. This second call off order is part of a framework contract for up to 175 trams with an initial call off of 60 trams signed in April 2018. The order is valued at approximately 67 million euro ($75 million US). First deliveries of the 30 additional five-car, 32-meter trams are planned from December 2020. Thomas Ryckalts, President of the STIB Board, said, “After a first order for 60 new trams, the STIB board took a decision in favor of our pas
Carpenter Technology Advances Aerospace Industry’s Shift to Electric18.6.2019 08:00:00 CEST | Pressemelding
LE BOURGET, France, June 18, 2019 (GLOBE NEWSWIRE) -- Carpenter Technology (NYSE: CRS) today announced its involvement with multiple OEMs to progress their electric aircraft aspirations. Carpenter Technology will provide advanced soft magnetic expertise and ultra-efficient electrical components to be used in R&D and demonstrator motors and engines, leading to construction of lighter-weight, longer-lasting electric propulsion systems. Alongside its partners, Carpenter Technology’s goal is to enable development of the highest power density motors available. “As the industry leader in electric propulsion material solutions, we are well positioned to support the development of electric systems to power the aircraft of tomorrow,” says Marshall Akins, Carpenter Technology’s Vice President, Aerospace Markets. “Our long history and comprehensive knowledge of how to develop and process these type of material solutions and then translate them into finished components so they function successfull
WillScot Announces Appointment of General Counsel17.6.2019 22:29:00 CEST | Pressemelding
BALTIMORE, June 17, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (Nasdaq: WSC) today announced the appointment of Mr. Hezron Timothy Lopez to serve as the Company’s Vice President, General Counsel & Corporate Secretary, effective June 17, 2019. Mr. Lopez joins WillScot after having served from 2012 to 2018 as Senior Vice President, General Counsel and Corporate Secretary of Herman Miller, Inc., a Nasdaq-listed manufacturer of home and office furniture. From 2008 to 2012, Mr. Lopez served as Associate General Counsel and Head of Merger & Acquisition, Commercial and International for A. O. Smith Corporation, a manufacturer of water heating equipment and water treatment products. About WillScot Corporation Headquartered in Baltimore, Maryland, WillScot (Nasdaq: WSC) is the public holding company for the Williams Scotsman family of companies and is the specialty rental services market leader providing innovative modular space and portable storage solutions across North Americ
Cineworld Group and Cinionic Strike 1,000+ Unit Deal to Roll Out Acclaimed Barco Laser Projectors to Theaters Worldwide17.6.2019 18:05:00 CEST | Pressemelding
Cineworld embarks on global renewal with Cinionic, powered by award-winning projection portfolio and enhanced services KORTRIJK, Belgium, June 17, 2019 (GLOBE NEWSWIRE) -- Cinionic, the Barco, CGS, and ALPD cinema joint venture providing a new visual standard with enhanced services and technology solutions, announces a significant expansion in its relationship with one of the world’s largest theater chains, Cineworld Group plc (LON:CINE), to continue delivering an elevated movie-going experience for audiences worldwide. Cinionic will illuminate Cineworld Group operated theaters in the U.S., EU and UK with enhanced services and award-winning portfolio of Barco laser projectors, including the newly launched Barco Series 4. Over the next 18 months, Cineworld will upgrade and deploy over 1,000 projectors worldwide with Barco Laser solutions to deliver a new visual standard in cinema, supported by Barco Alchemy media servers and maintained for the next decade through Cinionic’s enhanced ser